SEC Form 4 · accession 0001209191-18-063663
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Schiermeier
Officer — EVP, Dev and Corp Strategy
Period of report
Dec 18, 2018
Accepted (ET)
Dec 20, 2018 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.58 | Dec 18, 2018 | A | 81,000 | A | — | Dec 17, 2028 | Common Stock | 81,000 | 81,000 | D |
Explanation of responses
- F1This option was granted on December 18, 2018 with respect to 81,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.